Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

BofA Securities has upgraded Fulcrum Therapeutics FULC ahead of the company's phase 3 losmapimod readout, expected by the end of October for Facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare genetic muscle disease affecting a child's facial muscles, shoulders, upper arms, and lower legs. These muscles weaken and shrink (atrophy). The analyst notes that although a previous pivotal study failed using the DUX4 expression endpoint, the company conducted a post-hoc analysis and designed a new study w ...